Insulin detemir results in less weight gain than NPH insulin when added to oral agents in type 2 diabetes, with this advantage increasing with baseline obesity

被引：0

作者：

Hermansen, K

Tamer, SC

机构：

[1] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark

[2] Novo Nordisk, Copenhagen, Denmark

来源：

DIABETOLOGIA | 2005年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：A4 / A5

页数：2

共 50 条

[1] The advantage of less weight gain increases with baseline obesity when insulin detemir rather than NPH insulin is added to oral agents in type 2 diabetes
Hermansen, K
Tamer, SC
DIABETES, 2005, 54 : A67 - A67
[2] Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index
Rašlová K.
Tamer S.C.
Clauson P.
Karl D.
Clinical Drug Investigation, 2007, 27 (4) : 279 - 285
[3] Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index
Raslova, Katarina
Tamer, Soren Can
Clauson, Per
Karl, Diane
CLINICAL DRUG INVESTIGATION, 2007, 27 (04) : 279 - 285
[4] Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with Type 2 diabetes
Hermansen, K
Derezinski, T
Kim, H
Gall, MA
DIABETOLOGIA, 2004, 47 : A273 - A274
[5] Insulin detemir is associated with less weight gain than NPH insulin, especially in the very obese, when used in basal bolus therapy for patients with type 2 diabetes
Raslova, K
Karl, D
Tamer, SC
DIABETOLOGIA, 2005, 48 : A306 - A306
[6] Once-daily insulin detemir added to oral antidiabetic drugs results in less weight gain and a trend for reduced hypoglycaemia in comparison to NPH insulin in Japanese patients with type 2 diabetes
Tajima, N.
Iwamoto, Y.
Kaku, K.
Kawamori, R.
Nishida, T.
Kobayashi, M.
DIABETOLOGIA, 2006, 49 : 609 - 609
[7] Lower risk of hypoglycemia at each level of glycemic control when insulin detemir is added to oral agents compared to NPH insulin in patients with type 2 diabetes
Kolendorf, K
Kim, H
DIABETES, 2005, 54 : A121 - A121
[8] Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain
Rosenstock, Julio
Davies, Melanie
Home, Philip D.
Larsen, Jens
Tamer, Soren C.
Schernthaner, Guntram
DIABETES, 2006, 55 : A132 - A132
[9] Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients -: The PREDICTIVE™ BMI clinical trial
Montanana, C. Fajardo
Herrero, C. Hernandez
Fernandez, M. Rivas
DIABETIC MEDICINE, 2008, 25 (08) : 916 - 923
[10] Treatment with insulin detemir provides improved glycaemic control and less weight gain compared to NPH insulin in people with diabetes
Garber, AJ
Kim, H
Draeger, E
DIABETOLOGIA, 2004, 47 : A58 - A58

← 1 2 3 4 5 →